O’Neil Health Care Weekly

XLV gained 1.3% last week and is now testing key resistance at its rolling 50-DMA ($135.83). Near-term support is now the rising 21-
DMA ($133.39) followed by ~$130. Its RS line remains near multi-decade lows, still warranting an underweight sector positioning.

O’Neil Market View

The U.S. market is in a Confirmed Uptrend. Indices rose 1–2% this week and are approaching all-time highs ( 6,147, 20,204) which is less than ~3% away. The first level of support for the S&P 500 and Nasdaq is at their 10-DMA (5,935; 19,254). The distribution day count stand at four and three, respectively, with one day expiring on the S&P 500 next week.

O’Neil Health Care Weekly

XLV gained 1.8% last week, rallying from YTD lows and back into rolling 21-DMA ($133.40) resistance. Though the sector continues
to trade near long-term support at ~$130, its RS line remains near all-time lows, still warranting an underweight sector positioning.

O’Neil Market View

U.S. Market

 

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq rose 1.9% and 2.0%, respectively, for the week. Indices are still testing resistance near 5,970/19,200 and have immediate support at their rising 21-DMA (5,802/18,617). The distribution day count remains at three and two, respectively.

IPO Rewind

Attached is our monthly IPO Rewind report. This report identifies a select group of IPOs or spin-offs that have priced in the last three years, giving them time to digest any initial volatility. Our selected ideas display positive fundamental trends with strong top- and bottom-line consensus estimates, and IPO Rewind provides an efficient way to review these ideas that we believe warrant attention.

O’Neil Health Care Weekly

XLV fell over 2% last week after hitting resistance at the falling 21-DMA ($133.96). Though the index is trading near support between
$127-$130, its RS line remains near all-time lows, still warranting an underweight sector positioning.

O’Neil Market View

U.S. Market
The U.S. market remains in a Confirmed Uptrend. The S&P 500 and the Nasdaq declined ~2% this week and
breached their respective 10-DMA (5,838, 18,794). The next level of support for both indices is near their converging 100-
and 200-DMA (5,773, 18,413). The distribution day count on the S&P 500 and the Nasdaq increased to three and two,
respectively.

O’Neil Health Care Weekly

Sector Thoughts

XLV hit new 52-wk lows last Wednesday before rallying to close up 31bps on the week. The range of support is between $127.35 to $130, with near-term resistance still at the falling 21-DMA ($135.11; +1.5%). Though the sector is again trading near long-term support, its RS line is now hitting its lowest levels since this ETF launched 25 years ago. We continue to recommend an underweight sector positioning. 

O’Neil Market View

U.S. Market

 

The U.S. market remains in a Confirmed Uptrend. This week, the S&P 500 gained ~5%, while the Nasdaq was up ~7%, both retaking resistance at 100-DMA and 200-DMA. Support is at their 200-DMA (5,760/18,359) with only one distribution day on the S&P 500.

 

To close the week, all sectors except for Health Care are back above their 50-DMA. Over the last five sessions, Consumer Cyclical, Technology, and Transportation rose over 7% apiece, Energy, Capital Equipment, Financial, and Retail rose 3-5%. Consumer Staple, Utility, Health Care, and Basic Material lagged but still managed gains

O’Neil Health Care Weekly

XLV declined 4.2% last week unable to close above falling 21-DMA ($137) resistance. The next level of support is YTD lows at
$129.66. Its RS line is back to testing lows, still warranting an underweight sector positioning.